USE OF MITOXANTRONE LIPOSOME IN COMBINATION WITH CAPECITABINE IN TREATING NASOPHARYNGEAL CARCINOMA

Use of a mitoxantrone liposome and capecitabine in treating nasopharyngeal carcinoma, in particular recurrent and/or metastatic nasopharyngeal carcinoma. The present invention further provides a method for treating nasopharyngeal carcinoma, in particular recurrent and/or metastatic nasopharyngeal carcinoma, the method comprising administering a therapeutically effective dose of the mitoxantrone liposome and capecitabine to a patient with nasopharyngeal carcinoma. The combination of the mitoxantrone liposome and capecitabine exhibits superior efficacy in patients with nasopharyngeal carcinoma, thereby providing a new treatment option for patients with nasopharyngeal carcinoma..

Medienart:

Patent

Erscheinungsjahr:

2024

Erschienen:

2024

Enthalten in:

Europäisches Patentamt - (2024) vom: 07. März Zur Gesamtaufnahme - year:2024

Sprache:

Englisch

Beteiligte Personen:

LI CHUNLEI [VerfasserIn]
LIU YANPING [VerfasserIn]
LI MENGMENG [VerfasserIn]
HUANG WEI [VerfasserIn]
DU YANLING [VerfasserIn]
HE LIJUAN [VerfasserIn]
WANG SHIXIA [VerfasserIn]
DONG QI [VerfasserIn]
WANG DONG [VerfasserIn]
XUE JIANFEI [VerfasserIn]

Links:

Volltext [kostenfrei]

Themen:

Sonstige Themen:
615
A61K: Preparations for medical, dental, or toilet purpose (...)
A61P: Specific therapeutic activity of chemical compounds (...)
che

Anmerkungen:

Source: www.epo.org (no modifications made), First posted: 2024-03-07, Last update posted on www.tib.eu: 2024-04-10, Last updated: 2024-04-19

Patentnummer:

WO2024046246

Förderinstitution / Projekttitel:

PPN (Katalog-ID):

EPA000949086